A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use new ...